Legend Biotech (LEGN) Payables (2019 - 2026)
Legend Biotech's (LEGN) quarterly Payables came in at $74.3 million in Q1 2026, up 27.79% YoY from $58.1 million in Q1 2025, and down 10.48% on a QoQ basis from $83.0 million in Q4 2025.
Legend Biotech (LEGN) Payables (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Payables data on file, last reported at $74.3 million in Q1 2026.
- Quarterly Payables rose 27.79% year-over-year to $74.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74.3 million (up 27.79% YoY) and the FY2025 annual result came in at $83.0 million, up 115.03% from the prior year.
- Payables eased to $74.3 million in Q1 2026, from $83.0 million in the prior quarter.
- In the past five years, Payables ranged from a high of $102.5 million in Q3 2025 to a low of $17.2 million in Q3 2023.
- A 5-year average of $45.9 million and a median of $38.6 million in 2024 frame the typical range for Payables.
- Annual changes were most pronounced in 2022 — Payables jumped 201205.83% — and 2023, when it retreated 6.8%.
- Tracing LEGN's Payables over 5 years: stood at $32.9 million in 2022, then retreated by 6.8% to $30.7 million in 2023, then advanced by 25.92% to $38.6 million in 2024, then soared by 115.03% to $83.0 million in 2025, then slipped by 10.48% to $74.3 million in 2026.
- The last three Payables figures came in at $74.3 million (Q1 2026), $83.0 million (Q4 2025), and $102.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 77.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.30 Mn |
| Mar 31, 2026 | 74.30 Mn |
| Dec 31, 2025 | 83.00 Mn |
| Sep 30, 2025 | 102.46 Mn |
| Jun 30, 2025 | 75.36 Mn |
| Mar 31, 2025 | 58.14 Mn |
| Dec 31, 2024 | 38.60 Mn |
| Sep 30, 2024 | 26.91 Mn |
| Jun 30, 2024 | 39.49 Mn |
| Mar 31, 2024 | 39.49 Mn |
| Dec 31, 2023 | 30.66 Mn |
| Sep 30, 2023 | 17.17 Mn |
| Jun 30, 2023 | 21.54 Mn |
| Mar 31, 2023 | 29.81 Mn |
| Dec 31, 2022 | 32.89 Mn |
| Mar 31, 2022 | 19.42 Mn |
| Dec 31, 2021 | 14.09 Mn |
| Sep 30, 2021 | 11.59 Mn |
| Jun 30, 2021 | 11.00 Mn |
| Mar 31, 2021 | 9,649.00 |